New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
07:15 EDTTKMR, GSK, NNVC, BCRXWHO says ethical to offer unproven interventions in light of Ebola outbreak
The World Health Organization issued a statement that read in part: "West Africa is experiencing the largest, most severe and most complex outbreak of Ebola virus disease in history. Ebola outbreaks can be contained using available interventions like early detection and isolation, contact tracing and monitoring, and adherence to rigorous procedures of infection control. However, a specific treatment or vaccine would be a potent asset to counter the virus...In the particular circumstances of this outbreak, and provided certain conditions are met, the panel reached consensus that it is ethical to offer unproven interventions with as yet unknown efficacy and adverse effects, as potential treatment or prevention." Publicly traded companies that have confirmed development activities on Ebola treatments include Tekmira Pharmaceuticals (TKMR), GlaxoSmithKline (GSK), NanoViricides (NNVC) and BioCryst (BCRX). Reference Link
News For TKMR;GSK;NNVC;BCRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 14, 2014
10:10 EDTBCRX, GSK, TKMRNIH director says supporting BioCryst, Chimerix Ebola treatments
Subscribe for More Information
09:04 EDTBCRX, TKMRChinese company says drug can cure Ebola, Reuters reports
Subscribe for More Information
05:40 EDTTKMRTekmira partner Alnylam reports positive clinical data for Patisiran study
Tekmira Pharmaceuticals (TKMR) reported that Alnylam Pharmaceuticals (ALNY) presented six-month clinical data for the ongoing Patisiran Phase II Open Label Extension, or OLE, study in patients with Familial Amyloidotic Polyneuropathy, or FAP. Patisiran is an RNAi therapeutic targeting transthyretin, or TTR, in development for the treatment of TTR-mediated amyloidosis, or ATTR, which is enabled by Tekmira's lipid nanoparticle, or LNP, technology. Alnylam presented data at the American Neurological Association's 2014 Annual Meeting. Results showed a mean 0.95 point decrease in modified Neuropathy Impairment Score at six months in 19 patients with mNIS+7 data available for the current analysis. This decrease in neuropathy progression compares favorably with the 7 to 10 point increase in mNIS+7 at six months that can be estimated from historical data sets in untreated FAP patients with similar baseline characteristics.
October 13, 2014
07:12 EDTTKMR, GSKOligonucleotide Therapeutics Society to hold annual meeting
Subscribe for More Information
07:11 EDTTKMRTekmira volatility elevated, Texas health-care worker tests positive for Ebola
Subscribe for More Information
October 12, 2014
19:26 EDTTKMR, BCRXPatient being evaluated at Boston hospital for possible Ebola, Boston Globe says
Health officials say that a man that recently traveled to Liberia is being assessed at Beth Israel Deaconess hospital in Boston for the Ebola virus, the Boston Globe says. Drug companies that are working on experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Reference Link
19:12 EDTBCRX, TKMRCDC confirms Texas healthcare worker positive for Ebola
Subscribe for More Information
14:18 EDTTKMR, BCRXNY's JFK Airport begins Ebola screenings, WSJ says
Subscribe for More Information
12:48 EDTBCRX, TKMRTexas health-care worker tests positive for Ebola, WSJ says
Subscribe for More Information
October 10, 2014
10:54 EDTTKMR, BCRXMapp looking to up production of experimental Ebola treatment, WSJ says
Mapp Biopharmaceutical is aiming to broaden the manufacturing of its experimental Ebola treatment, ZMapp, according to The Wall Street Journal, citing comments from the company. Mapp said that the treatment was given to a few infected individuals prior to supplies running out two months ago. Drug companies that are working on experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Reference Link
October 9, 2014
14:55 EDTBCRX, TKMRHospital says deputy showing no signs of Ebola, AP reports
Subscribe for More Information
14:24 EDTBCRX, TKMRCDC head compares Ebola to AIDS, Washington Post says
Subscribe for More Information
14:13 EDTBCRX, TKMRFirst Ebola vaccine trial in West Africa started, NBC News reports
Subscribe for More Information
12:06 EDTTKMR, BCRXLakeland Industries continues surge amid Ebola fears
Subscribe for More Information
07:02 EDTGSKIsis Pharmaceuticals receives $18M milestone payment from GlaxoSmithKline
Subscribe for More Information
05:50 EDTTKMRStocks with implied volatility movement; ARWR TKMR
Stocks with implied volatility movement; Arrowhead (ARWR) 158, Tekmira (TKMR) 130 according to iVolatility.
October 8, 2014
11:59 EDTTKMRTekmira volatility increases after Ebola patient dies
Subscribe for More Information
11:22 EDTTKMR, BCRXChimerix falls after Ebola patient taking experimental drug dies
Shares of Chimerix (CMRX) are moving lower after the Texas Health Presbyterian Hospital Dallas announced that Thomas Eric Duncan succumbed to Ebola. Duncan was being treated with Chimerix's experimental drug Brincidofovir. Shares of Chimerix dropped 9% following the news to $30.19. Other makers of experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT) and BioCryst (BCRX).
07:11 EDTBCRXEuropean Academy of Dermatology and Venereology to hold a conference
23rd EADV Congress is being held in Amsterdam, The Netherlands on October 8-12.
06:11 EDTGSKNovartis says expects three executive committee members to leave
Novartis (NVS) confirmed that following completion of the transactions with GlaxoSmithKline (GSK) and Eli Lilly and Company (LLY) in the coming months, that the three business leaders of the Novartis divisions at the center of the transaction will leave the Executive Committee of Novartis. The expected changes to the ECN are subject to the closing of the transactions announced on April 22 - Novartis expects the transaction with GSK to be completed in the first half of 2015, and the transaction with Eli Lilly for its Animal Health Business to close in the first quarter of 2015. George Gunn, currently Division Head, Novartis Animal Health, will reach his contractual retirement age in July 2015 and will retire from Novartis. Upon closing of the Animal Health transaction with Lilly he will leave the ECN. Brian McNamara, currently Division Head, Novartis OTC, will transition to GSK as Head of Americas and Europe for the consumer health businesses, reporting to the President of GSK Consumer Healthcare, effective at closing of the transaction. Andrin Oswald, currently Division Head, Novartis Vaccines, will be leaving Novartis to pursue other opportunities following closing of the transaction with GSK.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use